您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > VR23
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
VR23
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
VR23图片
CAS NO:1624602-30-7
包装与价格:
包装价格(元)
10mM (in 1mL DMSO)电议
5mg电议
10mg电议
50mg电议
100mg电议

产品介绍
VR23 是一种小分子,可有效抑制胰蛋白酶样蛋白酶体 (IC50=1 nM)、糜蛋白酶样蛋白酶体 (IC50=50-100 nM) 和半胱天冬酶样蛋白酶体 (IC50=3 μM) 的活性。
Cas No.1624602-30-7
化学名7-chloro-4-(4-((2,4-dinitrophenyl)sulfonyl)piperazin-1-yl)quinoline
Canonical SMILESClC1=CC2=C(C(N3CCN(S(C4=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C4)(=O)=O)CC3)=CC=N2)C=C1
分子式C19H16ClN5O6S
分子量477.88
溶解度≥ 45.55mg/mL in DMSO
储存条件Store at -20℃
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

VR23 is an effective proteasome inhibitor, with IC50 values of 3 μmol/L, 1 nmol/L, and 50-100 nmol/L to inhibit activities of caspase-like proteasomes, trypsin-like proteasomes, and chymotrypsin-like proteasomes, respectively [1].

As a regulator, the ubiquitin-proteasome system is important for cell growth and apoptosis [2]. The ubiquitin-proteasome pathway is critical in the regulated degradation of proteins involved in tumor growth and cell cycle control [3].

Treatment with VR23 made cancer cells undergo an abnormal centrosome amplification cycle. This cycle was caused by the accumulation of ubiquitinated cyclin E. Bortezomib is clinically approved as a chymotrypsin-like proteasome inhibitor. VR23 in combinations with bortezomib, caused a synergistic effect in killing multiple myeloma cells. This synergistic effect was also effective to myeloma cells resistant to bortezomib [1].

In vivo, VR23 was effective in controlling metastatic breast cancer cells and multiple myelomas [1]. In engrafted animals, the treatment with VR23 at 30 mg/kg twice per week for three weeks inhibited tumor growth effectively. Following 24 hours pre-treatment with paclitaxel at 20mg/kg/week, the administration of VR23 enhanced the anti-tumor activity of paclitaxel by 70%. Histological data showed that VR23 substantially decreased mitotic index, inhibited tumor infiltration into surrounding tissues and remarkably reduced tumor cell proliferation and angiogenesis [4].

References:
[1].  Pundir S, Vu HY, Solomon VR, et al. VR23: A Quinoline-Sulfonyl Hybrid Proteasome Inhibitor That Selectively Kills Cancer via Cyclin E-Mediated Centrosome Amplification. Cancer research, 2015, 75(19): 4164-4175.
[2].  Almond JB, Cohen GM. The proteasome: a novel target for cancer chemotherapy. Leukemia, 2002, 16(4): 433-443.
[3].  Adams J, Palombella VJ, Sausville EA, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer research, 1999, 59(11): 2615-2622.
[4].  Vu HYT, Pundir S, Solomon RV, et al. Anticancer effects and mechanism of VR23, a novel chloroquine derivative. Cancer Research, 2014, 74(19 Supplement): 4545-4545.